Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Dudin

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|February 27, 2023
[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results]A N Boyko, K Z Bakhtiyarova, O V Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 8, 2025
[Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis]A N Boyko, V M Alifirova, Z A Goncharova, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 10, 2023
[Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]A N Boyko, V M Alifirova, I G Lukashevich, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|April 27, 2024
[Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]A N Boyko, V M Alifirova, I G Lukashevich, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|February 27, 2023
[Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results]A N Boyko, K Z Bakhtiyarova, O V Boyko, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 8, 2025
[Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis]A N Boyko, V M Alifirova, Z A Goncharova, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|August 10, 2023
[Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]A N Boyko, V M Alifirova, I G Lukashevich, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|April 27, 2024
[Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS]A N Boyko, V M Alifirova, I G Lukashevich, et al.
Pageof 3